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instrument has ﬁ ve functional scales (physical, role, cognitive, emotional, and social), 
three symptom scales (fatigue, pain, and emesis), and a global health/quality of life 
scale. The remaining single items assess dyspnoea, appetite loss, sleep disturbance,
constipation, and diarrhoea. The analyses focused on intraclass correlation coefﬁ cients 
(ICCs), comparing the ICC 95% lower conﬁ dence interval with a critical value of 
0.70. RESULTS: Subjects who did not complete the second assessments within 72 
hours or who had score differences on the scales or items exceeding two standard
deviations were excluded from the per protocol analyses. The sample sizes used in the
per protocol analyses ranged from 112 to 115 subjects. The ICCs for the 9 multi-item
scales were all above 0.69, ranging from 0.698 to 0.926 (ICC 95% lower CI range:
0.608 to 0.901). All of the scales were signiﬁ cantly different from our threshold reli-
ability of 0.70, with the exception of the cognitive functioning scale. The ICCs for the
6 single items ranged from 0.782 to 0.908 (ICC 95% lower CI range: 0.714 to 0.876) 
and all were statistically different from 0.70. The evidence supports the stability of 
the scores obtained on the IVR version of the QLQ-C30 upon repeated measurement. 
CONCLUSIONS: The equivalence of the IVR and paper versions of the QLQ-C30
has been demonstrated elsewhere. This analysis provides additional evidence of the
test-retest reliability of the IVR version of the QLQ-C30.
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OBJECTIVES: Research indicates 18% to 96% of cancer patients experience fatigue
due to cancer or its treatment. Only one claim for “cancer-related fatigue” (CF) has
been granted by the US Regulatory Authorities. To date, the deﬁ nition or diagnosis
of CF remains a subject for debate within the clinical community. Although several
self-completed CF-speciﬁ c instruments are available, the lack of an accepted concep-
tual framework articulating those concepts important to patients has hampered 
research in this ﬁ eld. Developing a preliminary conceptual framework able to underpin
patients’ experience of CF is central to gather meaningful data. Qualitative articles 
with verbatim patient quotes were reviewed and synthesized to begin a large effort 
to develop such a framework. METHODS: A systematic search identiﬁ ed 95 articles 
published between 1996 and 2007 containing patient quotes. Search terms included
fatigue, tiredness, lassitude, weakness, or asthenia. Two researchers independently 
reviewed articles; 645 quotes were extracted and systematically analyzed to identify 
concepts and language used to describe patients’ CF experiences. RESULTS: CF is 
more intense than pre-diagnosis or treatment tiredness. Terms such as “overwhelm-
ing,” “unusual,” and “all-encompassing” were used to describe CF. Quotes referring
to “tiredness” were often associated with adverbs (very, extremely) or patients’ idi-
omatic phrases intensifying “tiredness” (e.g., “dead-tired”, “sick-tired”) to distinguish 
tiredness due to CF. Metaphors depicted the severity and debility associated with CF. 
CONCLUSIONS: Findings suggest that extant CF assessments fail to capture the 
unique experience of CF as described by patients. Publication bias and lack of primary
data from which quotes were drawn are study limitations. Rigorous qualitative 
research with patients with different types and stages of cancer is needed to concisely
and comprehensively describe the experience of CF and its impact.
PCN89
FACTORS IMPACTING THE HEALTH RELATED QUALITY
OF LIFE IN FEMALE BREAST CANCER PATIENTS – 
AN OBSERVATIONAL, CROSS-SECTIONAL STUDY
Cristino J, Piercy J, Worsfold A
Adelphi Group, Bollington, Cheshire, UK
OBJECTIVES: To estimate the impact of performance status (ECOG), age, concomi-
tant conditions, length of diagnosis, exposure to chemotherapy treatment and care-
giver need on health related quality of life (HRQoL) in 800 adult female breast cancer
patients in the USA and 5 European countries (France, Germany, Italy, Spain and UK). 
METHODS: Data were drawn from the Adelphi Breast Cancer Disease Speciﬁ c Pro-
gramme (DSP), a cross-sectional study of consulting patients, undertaken in 2007. 
Physicians collected data on the next 7 patients presenting with breast cancer during
the study period. Patients were asked to report on their HRQoL (FACT-B). OLS 
regressions were performed using STATA. Diagnostic tests were performed (joint sig-
niﬁ cance, misspeciﬁ cation and multicolinearity) and White standard errors were
applied. RESULTS: Eight hundred (Europe, 686; USA, 114) patient records were 
analysed. FACT-B scores were signiﬁ cantly impacted in line with worsening ECOG
performance status (Grade 1: 7.44, overall; 5.94, USA; 13.48, Europe; all p 
0.001: Grade 2: 14.92, overall; 13.45, USA; 19.39, Europe; all p  0.001: Grade
3: 22.04, overall; 20.87, USA; 21.94, Europe; all p  0.001, except USA, p  0.05).
No Grade 4 patients were present in the sample. FACT-B scores were lower overall 
and in Europe, in patients currently receiving chemotherapy (-9.13, overall; 9.78,
Europe; all p  0.001), those with a caregiver (5.64, overall; 7.05, Europe; all p 
0.001). Longer diagnosis (0.82, P  0.05) and presence of mental health related 
concomitant conditions (7.25, P  0.05) were signiﬁ cant in US patients only. Age and
heart related concomitant conditions were not signiﬁ cant. Models showed overall
robustness to the diagnostic tests performed. CONCLUSIONS: A signiﬁ cant associa-
tion was seen between the patient-reported FACT-B scores and the physician-reported 
ECOG performance status. The impact of the various factors identiﬁ ed, including 
chemotherapy use, mental health related concomitant conditions and time since diag-
nosis, can provide useful indicators to be taken into account in the management of 
breast cancer patients.
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OBJECTIVES: The objective of this analysis was to develop a new analytic methodol-
ogy to identify a clinically relevant cut-off point in the EORTC QLQ-C30 ordinal
pain score by comparing patient and clinician reporting for the same symptom. Ability 
to translate between clinician and patient reported symptoms will be useful in planned 
future analyses. METHODS: Closed European Organisation for Research and Treat-
ment of Cancer Randomized Controlled Trials, where the symptom pain was scored
at baseline by the patient (EORTC QLQ-C30) and the clinician [Common Toxicity
Criteria (CTC)], were pooled and analysed to test the optimal cut-off point. The CTC 
was dichotomized as 0,1,2 vs. 3,4; deﬁ ned as a clinical relevant cut-off point for clini-
cal practice. Percent agreement with various dichotomizations of the QLQ-C30 pain 
scale was calculated, and McNemar’s test applied. Veriﬁ cation of the accuracy and 
generalizibility of the ﬁ ndings was evaluated with a validation set and by applying the 
same cut-off point on another symptom, i.e. fatigue. RESULTS: Data were available 
for pain [number of trials (t)  8, number of patients (n)  1214] and fatigue [t  5, 
n  1237]. Model and validation set were obtained by splitting the dataset in half.
Percentage agreement and p values for McNemar tests, between patient and clinician 
dichotomized scores using different cut-off points for the QLQ-scale, were: median 
(2.19 vs. 2.19, 64%, p  .01), quartile (vs. 3.0, 81%, p  0.55), decile (4.0 vs. 
4.0, 85%, p  0.01). The quartile split reﬂ ects best the dichotomized CTC score. This 
was conﬁ rmed in the validation set (quartile cut-off point: 82%, p  0.86). However, 
when the quartile cut-off was applied to the QLQ-C30 fatigue scale, a signiﬁ cant dif-
ference (p  .01) between patient and clinician results was found. CONCLUSIONS:
Our results indicate that a quartile split of the QLQ-C30 pain score is optimal. 
However, a single cut-point may not generalize to other QLQ-C30 symptoms;
symptom-speciﬁ c cut-points may be required.
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OBJECTIVES: To examine what information that parents of children with life-limiting 
conditions want from physicians and whether the provision of this information pro-
motes parents’ trust in physicians. METHODS: We conducted telephone surveys from
November 2007 through April 2008 with a random sample of 266 parents whose
children had life-limiting conditions and enrolled in Florida’s State Title V Children 
with Special Health Care Needs Program. Parents were asked if they wanted informa-
tion about the following: the child’s quality of life, pain relief, prognosis, incorporating
spiritual beliefs into the treatment plan, how treatments might change the child’s
appearance, and clinical examination/laboratory results. We used the Wake Forest
Physician Trust Scale to measure parent’s trust in physicians. We tested the relation-
ships between parent’s age, race/ethnicity, education, marital status, and parent-
reported children’s health status and desired information. We also tested whether
provision of this desired information was associated with greater trust in physicians.
RESULTS: Most parents wanted information on their children’s quality of life (95%), 
followed by the prognosis (88%) and pain relief (84%). Forty-nine percent of the 
parents desired advice from family/friends. Compared to parents with a high school 
education or higher, parents with less than a high school education showed a greater 
desire for information on pain relief and spiritual belief (p  0.05). Compared to White 
non-Hispanic parents, Hispanic and Black non-Hispanic parents showed a greater
desire for information on the child’s prognosis, incorporating spiritual beliefs into the
treatment plan, and the impact of the treatment on the child’s appearance (p  0.05). 
Providing information on children’s quality of life and pain relief was associated with 
greater trust in physicians after adjusting for parental characteristics (p  0.05). 
CONCLUSIONS: Parents wanted information on their children’s quality of life more 
so than any other information category. Providing this information along with infor-
mation about pain relief increased the families’ trust in the physicians.
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OBJECTIVES: To examine the association between characteristics of parents whose 
children are diagnosed with life-limiting conditions, trust in physicians, and problems
in the shared decision making process. METHODS: This study using data collected 
